Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MTSRNASDAQ:RARENASDAQ:RTRXNASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMTSRMetsera$30.39+10.5%$23.12$12.30▼$35.19$3.19BN/A892,971 shs3.18 million shsRAREUltragenyx Pharmaceutical$37.04-0.3%$35.62$29.59▼$60.37$3.50B0.25843,407 shs1.23 million shsRTRXTravere Therapeutics$14.91-2.7%$26.56$8.98▼$24.96$761.19M0.67412,277 shs1.15 million shsVKTXViking Therapeutics$27.57-0.9%$25.97$18.92▼$81.73$3.10B0.654.03 million shs3.62 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMTSRMetsera+10.55%+8.07%+27.26%+21.75%+3,038,999,900.00%RAREUltragenyx Pharmaceutical-0.35%+2.49%+5.35%-3.37%-10.53%RTRXTravere Therapeutics0.00%+2.00%-23.48%-14.27%+114.87%VKTXViking Therapeutics-0.93%+5.55%-0.14%+3.96%-50.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMTSRMetseraN/AN/AN/AN/AN/AN/AN/AN/ARAREUltragenyx Pharmaceutical3.8092 of 5 stars3.51.00.03.82.02.50.6RTRXTravere TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AVKTXViking Therapeutics4.548 of 5 stars4.52.00.04.72.23.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMTSRMetsera 3.00Buy$47.0054.66% UpsideRAREUltragenyx Pharmaceutical 2.92Moderate Buy$88.77139.66% UpsideRTRXTravere Therapeutics 0.00N/AN/AN/AVKTXViking Therapeutics 3.00Buy$87.15216.12% UpsideCurrent Analyst Ratings BreakdownLatest RTRX, RARE, MTSR, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025RAREUltragenyx PharmaceuticalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$65.005/9/2025RAREUltragenyx PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$64.00 ➝ $65.004/29/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$104.004/28/2025VKTXViking TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.00 ➝ $75.004/24/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.004/24/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.004/8/2025VKTXViking TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$30.003/27/2025RAREUltragenyx PharmaceuticalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$104.00 ➝ $117.003/26/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.00(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMTSRMetseraN/AN/AN/AN/AN/AN/ARAREUltragenyx Pharmaceutical$590.69M5.93N/AN/A$2.76 per share13.42RTRXTravere Therapeutics$175.34M4.34N/AN/A$5.15 per share2.90VKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMTSRMetseraN/AN/A0.00∞N/AN/AN/AN/AN/ARAREUltragenyx Pharmaceutical-$569.18M-$5.88N/AN/AN/A-101.60%-193.80%-38.15%7/30/2025 (Estimated)RTRXTravere Therapeutics-$146.43M-$3.46N/AN/AN/A-49.13%-36.38%-14.90%N/AVKTXViking Therapeutics-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)Latest RTRX, RARE, MTSR, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025MTSRMetseraN/A-$1.03N/A-$1.03N/AN/A5/6/2025Q1 2025RAREUltragenyx Pharmaceutical-$1.54-$1.57-$0.03-$1.57$145.98 million$139.29 million4/23/2025Q1 2025VKTXViking Therapeutics-$0.31-$0.41-$0.10-$0.41N/AN/A3/26/2025N/AMTSRMetseraN/A-$3.52N/A-$3.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMTSRMetseraN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ARTRXTravere TherapeuticsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMTSRMetseraN/AN/AN/ARAREUltragenyx PharmaceuticalN/A2.372.65RTRXTravere Therapeutics0.667.237.14VKTXViking TherapeuticsN/A36.4736.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMTSRMetseraN/ARAREUltragenyx Pharmaceutical97.67%RTRXTravere TherapeuticsN/AVKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipMTSRMetseraN/ARAREUltragenyx Pharmaceutical5.50%RTRXTravere Therapeutics4.63%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMTSRMetsera81105.06 millionN/AN/ARAREUltragenyx Pharmaceutical1,31094.54 million86.99 millionOptionableRTRXTravere Therapeutics22151.05 millionN/ANot OptionableVKTXViking Therapeutics20112.31 million106.20 millionOptionableRTRX, RARE, MTSR, and VKTX HeadlinesRecent News About These CompaniesWas Jim Cramer Right to Favor Another Stock Over Viking Therapeutics (VKTX)?June 9 at 12:58 PM | msn.comViking Therapeutics, Inc. (NASDAQ:VKTX) Receives $87.15 Average Price Target from BrokeragesJune 9 at 2:23 AM | americanbankingnews.com1 Stock Down 34% This Year to Buy and HoldJune 8 at 5:55 AM | fool.com39,652 Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) Bought by RFG Advisory LLCJune 6, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Buy" by AnalystsJune 6, 2025 | marketbeat.comProfit Investment Management LLC Buys 44,055 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)June 2, 2025 | marketbeat.comDeutsche Bank AG Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)June 2, 2025 | marketbeat.comMIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires New Shares in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 31, 2025 | marketbeat.comPKO Investment Management Joint Stock Co Purchases Shares of 15,000 Viking Therapeutics, Inc. (NASDAQ:VKTX)May 30, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Shares Up 3.4% - Here's WhyMay 29, 2025 | marketbeat.comLighthouse Financial LLC Acquires Shares of 14,000 Viking Therapeutics, Inc. (NASDAQ:VKTX)May 29, 2025 | marketbeat.comViking Therapeutics: Obesity Candidates Must Prove Their Edge As Market Matures (Upgrade)May 29, 2025 | seekingalpha.comNovo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?May 27, 2025 | zacks.comWoodline Partners LP Raises Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 27, 2025 | marketbeat.comWaverly Advisors LLC Increases Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 25, 2025 | marketbeat.comCastleark Management LLC Trims Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 24, 2025 | marketbeat.comBank of America Corp DE Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 24, 2025 | marketbeat.comViking Therapeutics: Weight-Loss Story Remains IntactMay 22, 2025 | seekingalpha.comNationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Reduces Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)May 22, 2025 | marketbeat.comViking Therapeutics: A High Potential Biotech Play With Manageable RisksMay 20, 2025 | seekingalpha.comViking Therapeutics: Near-Term Catalysts And Competitor ReadoutsMay 20, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s Watching3 Stocks Getting Rare Double Upgrades From AnalystsBy Chris Markoch | June 6, 2025View 3 Stocks Getting Rare Double Upgrades From AnalystsKeep Your EYE on This Stock, It Just Got a Rare Double UpgradeBy Sam Quirke | May 15, 2025View Keep Your EYE on This Stock, It Just Got a Rare Double UpgradeRTRX, RARE, MTSR, and VKTX Company DescriptionsMetsera NASDAQ:MTSR$30.39 +2.90 (+10.55%) As of 06/9/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.Ultragenyx Pharmaceutical NASDAQ:RARE$37.04 -0.13 (-0.35%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$37.04 +0.01 (+0.01%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Travere Therapeutics NASDAQ:RTRXTravere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.Viking Therapeutics NASDAQ:VKTX$27.57 -0.26 (-0.93%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$27.62 +0.05 (+0.20%) As of 08:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Drops on S&P Snub—Is a Bigger Pullback Coming? 3 Tightly-Held Growth Stocks Set Up for Short Squeezes Palantir Stock Holds Support, Despite Political Backlash Science Applications International Is a Wicked Hot Buy in June Why Unity Software May Be the AI Breakout No One Saw Coming Tesla Stock Dips to Buy Zone—Robotaxi Catalyst Ahead? Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes MarketBeat Week in Review – 06/02 - 06/06 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
